Literature DB >> 18613838

Inhibition of the lymphotoxin pathway as a therapy for autoimmune disease.

Jeffrey L Browning1.   

Abstract

SUMMARY: The lymphotoxin (LT) system is part of the tumor necrosis factor family and is required for lymph node development. It has provided a wonderful tool for the dissection of processes critical not only for lymphoid organ development but also the maintenance of the adult immune architecture and the formation of ectopic organized lymphoid tissues in chronically inflamed sites. A soluble lymphotoxin-beta receptor-immunoglobulin (LTbetaR-Ig) fusion protein can block this pathway and is currently being tested in the treatment of autoimmune disease. This review focuses on the immunological consequences of combined LT and LIGHT inhibition with LTbetaR-Ig administration as distinct from the developmental biology.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18613838     DOI： 10.1111/j.1600-065X.2008.00633.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN： 0105-2896            Impact factor:   12.988


  50 in total

Review 1.  TNF superfamily in inflammatory disease: translating basic insights.

Authors:  Michael Croft; Wei Duan; Heonsik Choi; So-Young Eun; Shravan Madireddi; Amit Mehta
Journal:  Trends Immunol       Date:  2011-12-13       Impact factor: 16.687

2.  Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans.

Authors:  Mathangi Srinivasan; Ryan Flynn; Andrew Price; Ann Ranger; Jeffrey L Browning; Patricia A Taylor; Jerome Ritz; Joseph H Antin; William J Murphy; Leo Luznik; Mark J Shlomchik; Angela Panoskaltsis-Mortari; Bruce R Blazar
Journal:  Blood       Date:  2011-11-09       Impact factor: 22.113

Review 3.  Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses.

Authors:  João Pedro Pereira; Lisa M Kelly; Jason G Cyster
Journal:  Int Immunol       Date:  2010-06       Impact factor: 4.823

4.  Bronchus-associated lymphoid tissue in pulmonary hypertension produces pathologic autoantibodies.

Authors:  Kelley L Colvin; Patrick J Cripe; D Dunbar Ivy; Kurt R Stenmark; Michael E Yeager
Journal:  Am J Respir Crit Care Med       Date:  2013-11-01       Impact factor: 21.405

Review 5.  Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.

Authors:  Haidong Tang; Mingzhao Zhu; Jian Qiao; Yang-Xin Fu
Journal:  Cell Mol Immunol       Date:  2017-04-17       Impact factor: 11.530

6.  High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients.

Authors:  C S Horjus Talabur Horje; C Smids; J W R Meijer; M J Groenen; M K Rijnders; E G van Lochem; P J Wahab
Journal:  Clin Exp Immunol       Date:  2017-01-31       Impact factor: 4.330

Review 7.  Stromal cell regulation of homeostatic and inflammatory lymphoid organogenesis.

Authors:  Matthew J W Kain; Benjamin M J Owens
Journal:  Immunology       Date:  2013-09       Impact factor: 7.397

Review 8.  Lymphotoxin and TNF: how it all began-a tribute to the travelers.

Authors:  Nancy H Ruddle
Journal:  Cytokine Growth Factor Rev       Date:  2014-02-12       Impact factor: 7.638

9.  Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury.

Authors:  Sarah A Pendergrass; Everett Hayes; Giuseppina Farina; Raphael Lemaire; Harrison W Farber; Michael L Whitfield; Robert Lafyatis
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

10.  Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation.

Authors:  Tri Giang Phan; Jesse A Green; Elizabeth E Gray; Ying Xu; Jason G Cyster
Journal:  Nat Immunol       Date:  2009-06-07       Impact factor: 25.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.